MedTrace Logo

Autologous Platelet-Rich Plasma in the Management of Asherman Syndrome

NCT04308811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-03-16

No results posted yet for this study

Summary

The aim of the study is to find out the benefit of the platelet-rich plasma in preventing reformation of intrauterine adhesions after adhesiolysis in cases of Asherman syndrome

Conditions

  • Intrauterine Adhesion

Interventions

BIOLOGICAL

platelet rich plasma

Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions

COMBINATION_PRODUCT

amniotic membrane graft group

amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions

DEVICE

Intrauterine balloon

intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-10
Primary Completion
2020-02-20
Completion
2020-02-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04308811 on ClinicalTrials.gov